Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471810 | 0.88 | DPP4 (0.76) | DPP4CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL4459937 | 0.80 | FABP3 (0.52) | DPP4CYP3A4CYP2C9 | |
| SCHEMBL4475821 | 0.79 | DPP4 (0.83) | DPP4CYP3A4 | |
| SCHEMBL4470090 | 0.78 | DPP4 (0.52) | DPP4CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL4464555 | 0.77 | DPP4 (0.49) | DPP4CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL4464558 | 0.77 | DPP4 (0.49) | DPP4CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL4460195 | 0.76 | PLA2G2A (0.53) | DPP4CYP3A4 | |
| SCHEMBL3369601 | 0.76 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL4460206 | 0.76 | DPP4 (0.72) | DPP4CYP3A4 | |
| SCHEMBL3370993 | 0.75 | DPP4 (0.74) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831180-B1 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-1831180-B1 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1831180-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Bristol-Myers Squibb Company (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071762-A2 | PYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885CYP3A4 220/4885CYP2C19 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.